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Abstract. FOXP2 is altered in a variety of language disorders. We found reduced mRNA and protein expression of FOXP2 in
frontal cortex area 8 in Pick’s disease, and frontotemporal lobar degeneration-tau linked to P301L mutation presenting with
language impairment in comparison with age-matched controls and cases with parkinsonian variant progressive supranuclear
palsy. Foxp2 mRNA and protein are also reduced with disease progression in the somatosensory cortex in transgenic mice
bearing the P301S mutation in MAPT when compared with wild-type littermates. Our findings support the presence of FOXP2
expression abnormalities in sporadic and familial frontotemporal degeneration tauopathies.
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INTRODUCTION
Frontotemporal dementia (FTD) represents a
heterogeneous group of cognitive disorders that
generally affect language and behavior, eventually
leading to dementia. Clinically, several subgroups
have been proposed including a behavioral variant,
progressive non-fluent aphasia, semantic dementia,
and logopenic aphasia. The pathological hallmark
of the disease is frontotemporal lobar degenera-
tion (FTLD) [1, 2]. Microtubule-associated protein
tau gene (MAPT), located on chromosome 17, is
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causative of a subgroup of familial FTD categorized
as fFTLD-tau [3, 4].
Forkhead box P2 gene (FOXP2 in human, Foxp2 in
mouse) encodes a protein that belongs to the forkhead
box family of transcription factors. The gene struc-
ture is almost the same in mice and chimpanzees,
whereas orangutans show only minor changes in the
secondary structure, while a minor change at position
325 occurs in humans [5]. Disruption of FOXP2 leads
to language impairment [6]. FOXP2 is abnormally
regulated in several language disorders [7–12]. Cer-
tain FOXP2 polymorphisms modulate phenotypical
expression of FTD, leading to a decrease in verbal flu-
ency and decreased cortical volume in selected areas
such as the left inferior frontal cortex and Broca.
FOXP2 polymorphisms are risk factors for FTD
[13]. Interestingly, adult heterozygous Foxp2 mice
mutants emit abnormal ultrasonic vocalizations [14].
The present study was focused on learning whether
FOXP2 mRNA and protein expression are altered
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in the frontal cortex in human cases with spo-
radic FTLD-tau (sFTLD) and fFTLD-tau. Cases of
sFTLD-tau including Pick’s disease (PiD) and cases
of fFTLD-tau are represented by those bearing the
P301L mutation in MAPT. For comparative pur-
poses, the frontal cortex of cases with progressive
supranuclear palsy-parkinsonian variant (PSP-P) was
included as tauopathy with little cortical impairment.
To learn whether or not these changes are related to
cell loss at terminal stages in human cases, Foxp2
mRNA and protein expression were analyzed in the
somatosensory cortex of MAPT P301S transgenic
mice used as a model of fFTLD-tau at different
ages [15, 16]. Interestingly, newborn transgenic mice
exhibit abnormal ultrasonic vocalization [17], which
was interpreted in the present context as a counterpart
of language impairment in humans [18].
MATERIAL AND METHODS
Human brain tissue was obtained from the
Institute of Neuropathology Brain Bank (HUB-ICO-
IDIBELL Biobank, Barcelona, Spain) and Clinic
Hospital-IDIBAPS Biobank (Barcelona, Spain) fol-
lowing the guidelines of Spanish legislation and of the
local ethics committee. One hemisphere was immedi-
ately cut in coronal sections, 1 cm thick, and selected
areas of the encephalon were rapidly dissected, frozen
on metal plates over dry ice, placed in individual
air-tight plastic bags, numbered with water-resistant
ink, and stored at –80◦C. The other hemisphere was
fixed by immersion in 4% buffered formalin for 3
weeks for morphological study. Frontal cortex from
34 cases was used in the present study: 3 PiD, 11
PSP-P, 4 FTLD-tau (P301L), and 15 age-matched
controls. Cases with associated pathologies (e.g., vas-
cular diseases, synucleinopathies, TDP-43 pathies)
were excluded from the present study.
Male heterozygous transgenic mice expressing
human P301S tau (line PS19) and wild-type (WT)
littermates were killed by cervical dislocation at
1, 3, 6. and 10 months of age. Five animals per
age (1 to 10 months) and genotype were used in
this study. The generation of mice expressing the
human mutated form P301S tau has already been
described [15]. All animal procedures were carried
out following the guidelines of the European Com-
munities Council Directive 2010/63/EU and with the
approval of the local ethical committee of the Uni-
versity of Barcelona. The brain was rapidly removed
from the skull; the left hemisphere was dissected into
selected brain regions which were frozen and stored
at –80ºC until use for biochemical studies. The right
hemisphere was fixed in 4% buffered paraformalde-
hyde for histological study.
Human frontal cortex area 8 and murine somato-
sensory cortex samples were processed for qRT-
PCR and western blotting as detailed elsewhere
[16]. TaqMan RT-qPCR assay for Foxp2 (Mm0047
5030 m1) and FOXP2 (Hs00362818 m1) was per-
formed in duplicate on cDNA samples in 384-well
optical plates using an ABI Prism 7900 Sequence
Detection system (Applied Biosystems, Life Tech-
nologies, Waltham, MA, USA). Parallel assays
for each sample were carried out using probes
for X-prolyl aminopeptidase (aminopeptidase P)
1 (Xpnpep1) (Mm00460040 m1) to normalize mouse
samples and -glucuronidase (-GUS) (Hs009
39627 m1) in human cases. TaqMan PCR data
were captured using the Sequence Detection Soft-
ware (SDS version 1.9, Applied Biosystems). Assays
were performed without cDNA samples to ver-
ify the degree of contamination. Results in the
frontal cortex in human cases were analyzed with
1-way analysis of variance, followed by Dunnett’s
post hoc, while in murine samples 2-way analysis
of variance with genotype and age as between fac-
tors was followed by Tukey post hoc or Student
t-test when required. The significance level was set at
p < 0.05 for all experiments. Values were expressed as
the mean values ± standard error of the mean (SEM).
For western blotting, the membranes were first
incubated with the rabbit polyclonal anti-FOXP2
antibody (ab16045, Abcam, Cambridge, UK) used
at a dilution of 1:1,000, followed by the secondary
antibody (1:2,000, Dako, Carpinteria, CA, USA),
and then revealed with a chemiluminescence reagent
(ECL, Amersham, GE Healthcare, Buckinghamshire,
UK). -actin (1:30,000, Sigma-Aldrich, St Louis,
MO) was blotted in parallel in each membrane to
normalize protein loading. Densitometry of bands in
western blots was analyzed with the software TotaLab
(TL100 v.2006b).
RESULTS
FOXP2 mRNA and protein expression in the
frontal cortex in PiD, PSP-P, and FTLD-tau
(P301L)
A significant decrease in FOXP2 mRNA was found
in PiD and FTLD-tau (P301L) (p < 0.01 and p < 0.05,
respectively) when compared with controls. In con-
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trast, no difference in FOXP2 mRNA levels was
observed in frontal cortex area 8 in PSP-P (Fig. 1A).
Protein levels of FOXP2 were analyzed in the same
cases with western blotting. Three group bands of
approximately 140 kDa, 85 kDa, and 70 kDa were
detected in the immunoblots. The band of 140 kDa
was a single band, whereas the band of 85 kDa was
in fact a doublet, while the band of 75 kDa was com-
posed of three packet bands in human cases. The
triplet of 70 kDa was expressed in control and PSP-
P cases, whereas only the upper band of the triplet
was preserved in PiD and FTLD-tau. The doublet of
Fig. 1. A) FOXP2 mRNA and protein levels in frontal cortex 8
in three Pick’s disease (PiD) cases, three progressive supranuclear
palsy-parkinsonian variant (PSP-P) cases, and three frontotempo-
ral lobar degeneration-tau linked to P301L mutation (FTLD-tau)
cases, in comparison with fifteen control (Ctrl) cases. FOXP2
mRNA expression is significantly decreased in PiD and FTLD-
tau when compared with controls. Data in graphs (columns and
corresponding bars) represent mean values ± SEM of all cases
analyzed. B) Western blotting of FOXP2 reveals several bands in
human cases, one band of 140 kDa, a doublet of about 85 kDa, and
a triplet of about 70 kDa. Western blotting of FOXP2 shows a sig-
nificant reduction in PiD and FTLD-tau versus Ctrl. Data in graphs
(columns and corresponding bars) represent mean values ± SEM
of all cases analyzed by western blotting which includes three
PiD, three PSP-P, three FTLD-tau, and five controls). ∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.001 compared with controls (Dunnett’s
post hoc).
85kDa was only seen in control and PSP-P. The band
of 140 kDa was strong in control and PSP-P, weak in
PiD, and absent in FTLD-tau (P301L). Densitomet-
ric analysis showed significantly decreased FOXP2
expression in PiD and FTLD-tau (P301L) (p < 0.001)
when compared with control (Fig. 1B).
Foxp2 mRNA and protein expression in
somatosensory cortex of P301S transgenic mice
Foxp2 mRNA significantly increased with age in
WT mice aged 3 and 6 months when compared with
mice aged 1 month (p < 0.05), whereas no modi-
fications occurred in P301S transgenic mice with
age. However, the expression of Foxp2 mRNA was
significantly decreased in P301S transgenic mice
aged 6 months when compared with WT littermates
(p < 0.05) (Fig. 2A). No differences in Foxp2 mRNA
were observed in mice aged 10 months. FOXP2
immunoreactivity in mice was represented by three
bands of 140 kDa, 85 kDa, and 70 kDa. No dou-
blets or triplets were observed in mice, in contrast
to human cases. This may reflect species differences
in FOXP2, although modifications related to post-
mortem delay cannot be ruled out in human cases.
FOXP2 protein levels were significantly decreased in
P301S transgenic mice aged 6 months and 10 months
when compared with corresponding WT littermates
(p < 0.01 and p < 0.05, respectively). Moreover, a sig-
nificant reduction was also noted in P301S transgenic
mice aged 10 months when compared with 3-month-
old transgenic mice (p < 0.01) (Fig. 2B).
DISCUSSION
The present study shows decreased FOXP2 mRNA
and protein expression in the frontal cortex in PiD, a
paradigm of sFTLD-tau, and in FTLD cases bear-
ing the P301L mutation in MAPT [2–4, 19]. In
contrast, no modifications in the expression levels
of FOXP2 mRNA and protein were found in the
frontal cortex in PSP-P, a tauopathy with little cortical
involvement and no language disturbances [20]. This
observation suggests that FOXP2 associates with spo-
radic and familial FTLD-tau but not necessarily with
other diseases with abnormal hyper-phosphorylated
tau deposits such as PSP-P.
It can be argued that decreased FOXP2 mRNA and
protein levels in PiD and FTLD-P301L are due, at
least in part, to the severe neuronal cell loss found
in the frontal cortex at terminal stages of the dis-
ease. Transgenic mice bearing the P301S mutation
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Fig. 2. Foxp2 mRNA and protein expression in P301S transgenic
mice (P301S) and wild-type littermates (WT) at different ages.
A) Foxp2 mRNA expression increases at 3 and 6 months, but not
at month 10 compared with 1 month in WT, and not in P301S
transgenic mice. Foxp2 mRNA is reduced in P301S mice at the age
of 6 months. B) Western blotting reveals three bands in the cortex,
one band of 140 kDa, another of 85 kDa, and a third of 75 kDa.
Two representative cases per age and genotype were run in parallel
FOXP2 protein, as revealed by western blotting, is significantly
reduced at the ages of 6 and 10 months in P301S when compared
with WT mice. FOXP2 protein is also significantly reduced at
the age of 10 months when compared with 3 months in P301S
mice. Data in graphs (columns and corresponding bars) represent
mean values ± SEM of all cases analyzed (five animals per age and
genotype). ∗p < 0.05 and ∗∗p < 0.01, P301S compared with WT
(t-Student). #p < 0.05, WT aged 3 and 6 months compared with
WT aged 1 month (Tukey’s post hoc test). $$p < 0.01, P301S aged
10 months compared with P301S aged 3 months (Tukey’s post hoc
test).
in Mapt aged up to 10 months do not have neuron
loss in the somatosensory cortex [15, 16]. Yet Foxp2
mRNA is significantly reduced in the somatosensory
cortex in P301S transgenic mice at 6 months, as is
FOXP2 protein at 6 months and 10 months when
compared with corresponding WT littermates. There-
fore, reduced FOXP2 expression in the frontal cortex
occurs in PiD, human FTLD-P301L, and transgenic
mice bearing the P301S mutation in Mapt indepen-
dently of the presence or absence of neuron loss.
Together, these observations point to the likelihood
that FOXP2 underlies language disturbances in PiD
and fFTLD-tau.
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